drugset / Trial / NCT02685852

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

NCT02685852

Phase 1 Completed 11 enrolled University of Minnesota
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the effectiveness of exenatide in adults experiencing episodes of hyperinsulinemic hypoglycemia following Roux-en-Y bariatric surgery.

Timeline

Start
2016-02
Primary completion
2019-07-22
Completion
2019-07-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acarbose Unknown 25 mg
Comparator Exenatide Peptide 5 ug